Profile
| Metric | Value |
|---|---|
| Full Name | Ascendis Pharma A/S |
| Ticker | NASDAQ: ASND |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Denmark |
| IPO | |
| Indexes | Not included |
| Website | ascendispharma.com |
| Employees | 1,017 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $216.85 | |
| Price, 1D Change | +0.84% | |
| Market Cap | $13B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.33 | |
| Revenue | $393M | |
| Revenue, 1Y Change | +36.41% | |
| EPS | -$7.06 | |
| EPS, 1Y Change | +23.60% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$7.06 | |
| EPS Estimate | -$3.21 | |
| EPS Est. Change | +54.56% | |
| Revenue | $393.35M | |
| Revenue Estimate | $714.91M | |
| Revenue Est. Change | +81.75% | |
| Current Price | $216.85 | |
| Price Target | - | - |
| Price Tgt. Change | - | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $0.04 | -$9.25 | -23,218.00% | |
| -$6.59 | -$7.06 | -7.26% | |
| -$3.21 | N/A | +54.56% | |
| $3.50 | N/A | +149.59% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $288.35M | - | |
| $321.31M | $393.35M | +22.42% | |
| $714.91M | N/A | +81.75% | |
| $1.30B | N/A | +230.93% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +64.82% | |
| Price, 3Y | +88.52% | |
| Market Cap, 1Y | +68.27% | |
| Market Cap, 3Y | +101.53% | |
| Revenue, 1Y | +36.41% | |
| Revenue, 3Y | +4,178.53% | |
| EPS, 1Y | +23.60% | |
| EPS, 3Y | +14.66% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $216.85 | |
| SMA 200 | $186.25 | |
| SMA 200 vs Price | -14.11% | |
| SMA 50 | $207.33 | |
| SMA 50 vs Price | -4.39% | |
| Beta | 0.33 | |
| ATR | $10.53 | |
| 14-Day RSI | 55.58 | |
| 10-Day Volatility | 33.40% | |
| 1-Year Volatility | 41.47% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $393.35M | |
| EPS | -$7.06 | |
| Gross Profit | $333.14M | |
| Gross Margin | 84.69% | |
| Operating Profit | -$301.54M | |
| Operating Margin | -76.66% | |
| Net Income | -$408.97M | |
| Net Margin | -103.97% | |
| EBITDA | -$282.37M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | -8.10 | |
| Current Ratio | 1.17 | |
| Quick Ratio | 0.84 | |
| - | ||
| F-Score | 3 | |
| Altman Z-Score | 2.60 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 18.38 | |
| PB Ratio | -64.78 | |
| EV/EBITDA | -98.82 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | -$109.99M | |
| Cash & Equivalents | $582.24M | |
| Total Assets | $1.22B | |
| Current Assets | $1.10B | |
| Total Liabilities | $1.33B | |
| Current Liabilities | $944.70M | |
| Total Debt | $887.03M | |
| Short Term Debt | $508.99M | |
| Accounts Payable | $100.30M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $802.32M | |
| Operating Expenses | $634.68M | |
| Cost Of Goods Sold | $60.20M | |
| SG&A | $314.93M | |
| D&A | $19.16M | |
| Interest Expense | $0.00 | |
| Income Tax | $5.24M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$331.21M | |
| CFI | $7.44M | |
| CFF | $480.19M | |
| Capex | $1.54M | |
| Free Cash Flow | -$332.75M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | → | |
| TD Cowen | → | |
| Stifel | → | |
| Wedbush | → | |
| Raymond James | ||
| Cantor Fitzgerald | → | |
| JP Morgan | → | |
| B of A Securities | → | |
| JP Morgan | → | |
| Wells Fargo | → |
Analyst sentiment
Institutional ownership
Screeners with ASND
Data Sources & References
- ASND Official Website ascendispharma.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1612042/000119312525277622/0001193125-25-277622-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1612042/000095017025018852/0000950170-25-018852-index.htm
- ASND Profile on Yahoo Finance finance.yahoo.com/quote/ASND
- ASND Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/asnd
FAQ
What is the ticker symbol for Ascendis Pharma A/S?
The ticker symbol for Ascendis Pharma A/S is NASDAQ:ASND
Does Ascendis Pharma A/S pay dividends?
No, Ascendis Pharma A/S does not pay dividends
What sector is Ascendis Pharma A/S in?
Ascendis Pharma A/S is in the Healthcare sector
What industry is Ascendis Pharma A/S in?
Ascendis Pharma A/S is in the Biotechnology industry
What country is Ascendis Pharma A/S based in?
Ascendis Pharma A/S is headquartered in Denmark
When did Ascendis Pharma A/S go public?
Ascendis Pharma A/S initial public offering (IPO) was on January 28, 2015
Is Ascendis Pharma A/S in the S&P 500?
No, Ascendis Pharma A/S is not included in the S&P 500 index
Is Ascendis Pharma A/S in the NASDAQ 100?
No, Ascendis Pharma A/S is not included in the NASDAQ 100 index
Is Ascendis Pharma A/S in the Dow Jones?
No, Ascendis Pharma A/S is not included in the Dow Jones index
When was Ascendis Pharma A/S last earnings report?
Ascendis Pharma A/S's most recent earnings report was on November 12, 2025
When does Ascendis Pharma A/S report earnings?
The next expected earnings date for Ascendis Pharma A/S is February 11, 2026